SGN-1
- Generic Name
- SGN-1
- Drug Type
- Biotech
- Background
SGN-1 is a genetically modified strain of Salmonella enterica comprising methioninase.
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Guangzhou Sinogen Pharmaceutical Co., Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT05103345
- Locations
- 🇨🇳
Guangdong Clifford Hospital, Guangzhou, Guangdong, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, New Taipei, Taiwan
Study of SGN1 in Patients With Advanced Solid Tumor
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Guangzhou Sinogen Pharmaceutical Co., Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT05038150
- Locations
- 🇨🇳
Guangdong Clifford Hospital, Guangzhou, Guangdong, China
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Health Chao Family Comprehensive Cancer Center, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath